NPHC

Nutra Pharma Announces First Manufacturing Agreement

Mar 23, 2022

Nutra Pharma is announcing Avini Health as its first contract manufacturing partner Plantation, Florida, March 23, 2022 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is announcing their first agreement to...

Nutra Pharma Expands Manufacturing Capabilities

Mar 17, 2022

Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for new product launches for their OTC drugs and potential dietary supplements Plantation, Florida, March 17, 2022 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...

Nutra Pharma Letter to Shareholders

Jan 18, 2022

Nutra Pharma has published their annual letter to shareholders to the Company’s website Plantation, Florida, Jan. 18, 2022 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's...

Nutra Pharma Provides Business and Compliance Updates

Jul 26, 2021

Nutra Pharma is providing updates regarding their business plans, accounting and compliance Plantation, Florida, July 26, 2021 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, provided updates today on their...

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Jul 23, 2021

Nutra Pharma has filed an updated provisional patent for the protection of their intellectual property surrounding the use of RPI-78M and analogs of the drug as potential counter-measures against organophosphate nerve agents Plantation, Florida, July 23, 2021 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is...

Nutra Pharma Engages Government Affairs Consulting Firm

Jul 15, 2021

Nutra Pharma is working with Washington DC-based government affairs consultants and lobbyists to support their Nyloxin® line of pain relief products as well as act as liaisons to governmental agencies Plantation, Florida, July 15, 2021 -- McapMediaWire -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing...

Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings

Jun 8, 2021

Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin® line of pain relief products to their marketplace Plantation, Florida, June 8, 2021 — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away, Luxury Feet, and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency...

NEWSROOM

Categories

Mcap MediaWire - Costumer Service